argenx SE (ARGX): A Bull Case Theory

We came across a bullish thesis on argenx SE on Stock Analysis Compilation. In this article, we will summarize the bulls’ thesis on ARGX. argenx SE's share was trading at $661.83 as of August 8^th. ARGX’s trailing and forward P/E were 33.68 and 48.78 respectively according to Yahoo Finance.

Argenx SE is a biotechnology company focused on developing Vyvgart, a leading FcRn inhibitor for autoimmune diseases, positioning it for strong long-term growth despite recent sales setbacks. The company’s shares fell after first-quarter Vyvgart sales missed high investor expectations, primarily due to seasonal factors like insurance reverification and increased Medicare Part D utilization that led to higher discounts.

Nevertheless, ongoing discussions with management and neurologists affirm Vyvgart’s significant clinical value and its role as a key treatment option. The drug is successfully launching in key indications such as generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, showing solid adoption. Furthermore, the company’s pipeline offers promising expansion potential, as evidenced by encouraging Phase 2 data for myositis presented at a major medical conference.

This suggests Vyvgart’s efficacy may extend across a broader range of autoantibody-driven autoimmune conditions, supporting a compelling long-term growth outlook. Despite short-term volatility, Argenx’s core asset remains highly differentiated in the autoimmune market, with strong physician support and a growing patient base. The current share price appears to underappreciate the durable demand trajectory and the company’s capacity to capture incremental indications, presenting a compelling risk/reward opportunity for investors focused on innovative biotech with sustainable growth prospects.

Previously, we covered a bullish thesis on Argenx SE by FluentInQuality in May 2025, highlighting Vyvgart’s platform approach, broad autoimmune applications, and durable revenue. Since then, the stock price has appreciated by about 5.13% by May 2025, driven by strong clinical adoption. The thesis remains valid. Stock Analysis Compilation shares a similar view but emphasizes recent seasonal sales and short-term challenges.

Argenx SE is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 54 hedge fund portfolios held ARGX at the end of the first quarter which was 47 in the previous quarter. While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None.